ArticleCancer medicine2021
An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Ferroptosis-associated RNA-binding proteins predict clinical outcomes in head and neck squamous cell carcinoma.Translational cancer research · 2025Article
- Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy.Molecular and cellular biochemistry · 2024Review
- Deciphering COPS5 influence on immune infiltration and prognosis in head and neck squamous cell carcinoma.Heliyon · 2024Article
- The Role of Biomarkers in HPV-Positive Head and Neck Squamous Cell Carcinoma: Towards Precision Medicine.Diagnostics (Basel, Switzerland) · 2024Review
- Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma.Discover oncology · 2024Review
- Immune-Related Long Non-Coding RNA Signature Determines Prognosis and Immunotherapeutic Coherence in Esophageal Cancer.Cancer informatics · 2024Article
- Review
- Expression and molecular regulation of non-coding RNAs in HPV-positive head and neck squamous cell carcinoma.Frontiers in oncology · 2023Review
- The role of long non-coding RNAs in the pathogenesis of head and neck squamous cell carcinoma.Molecular therapy oncolytics · 2022Review
- Comprehensive Analysis of an Individualized Immune-Related lncRNA Pair Signature in Gastric Cancer.Frontiers in cell and developmental biology · 2022Article
- The role of long noncoding RNAs as regulators of the epithelial-Mesenchymal transition process in oral squamous cell carcinoma cells.Frontiers in molecular biosciences · 2022Review
- Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features.Bioengineered · 2021Article
- Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.Disease markers · 2021Article
- Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma.Frontiers in pharmacology · 2021Article
- Editorial: "Non-Coding RNAs in Head and Neck Squamous Cell Carcinoma".Frontiers in oncology · 2021Article
- A Novel Ferroptosis-Related Gene Signature to Predict Prognosis in Patients with Head and Neck Squamous Cell Carcinoma.Disease markers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we developed a long noncoding RNA (lncRNA)-based prognostic signature for stratification of patients with head a nd neck squamous cell carcinoma (HNSCC). In total, 493 HNSCC samples obtained from the Cancer Genome Atlas database were divided into training and testing cohorts (3:2 ratio). We identified 3913 immune-related lncRNAs in the HNSCC training cohort by Pearson correlation analysis; only seven were independently associated with overall survival and were used to develop an immune-related lncRNA prognostic signature (IRLPS) grouping of HNSCC patients into high- and low-IRLPS subgroups. Univariate and multivariate Cox analyses revealed that low-IRLPS patients had a better prognosis in all the cohorts, which was retained after stratification by sex, grade, and HPV status. Although the TNM stage was also an independent prognostic factor, the IRLPS had a better discriminability with higher AUC at the 3- and 5-year follow-ups in all cohorts. Low-IRLPS samples had more immune cell infiltration and were enriched in immune-related pathways, while high- IRLPS samples were enriched in metabolic pathways. A nomogram constructed including age, TNM stage, and IRLPS showed good calibration. Thus, IRLPS improves the prognostic prediction and also distinguishes different tumor microenvironment (TME) in HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.